OBJECTIVE: Variations in cytochrome P450 (CYP) genes have been shown to be associated with both accelerated and delayed pharmacokinetic clearance of many psychotropic medications. Citalopram is metabolized by three CYP enzymes. CYP2C19 and CYP3A4 play a primary role in citalopram metabolism, whereas CYP2D6 plays a secondary role. METHODS: The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram. The primary analyses were of the White non-Hispanic patients adherent to the study protocol (n= 1074). RESULTS: Generally, patients who had CYP2C19 genotypes associated with decreased metabolism were less likely to tolerate citalopram than those with increased metabolism, although this difference was not statistically significant (P = 0.06). However, patients with the inactive 2C19*2 allele had significantly lower odds of tolerance (P = 0.02). Patients with the poor metabolism CYP2C19 genotype-based category who were classified as citalopram tolerant were more likely to experience remission (P = 0.03). No relationship between CYP2D6 genotype-based categories and either remission or tolerance was identified, although exploratory analyses identified a potential interaction between CYP2C19 and CYP2D6 effects. CONCLUSION: Despite several limitations including the lack of serum drug levels, this study showed that variations in CYP2C19 were associated with tolerance and remission in a large sample of White non-Hispanic patients treated with citalopram.
OBJECTIVE: Variations in cytochrome P450 (CYP) genes have been shown to be associated with both accelerated and delayed pharmacokinetic clearance of many psychotropic medications. Citalopram is metabolized by three CYP enzymes. CYP2C19 and CYP3A4 play a primary role in citalopram metabolism, whereas CYP2D6 plays a secondary role. METHODS: The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram. The primary analyses were of the White non-Hispanic patients adherent to the study protocol (n= 1074). RESULTS: Generally, patients who had CYP2C19 genotypes associated with decreased metabolism were less likely to tolerate citalopram than those with increased metabolism, although this difference was not statistically significant (P = 0.06). However, patients with the inactive 2C19*2 allele had significantly lower odds of tolerance (P = 0.02). Patients with the poor metabolism CYP2C19 genotype-based category who were classified as citalopram tolerant were more likely to experience remission (P = 0.03). No relationship between CYP2D6 genotype-based categories and either remission or tolerance was identified, although exploratory analyses identified a potential interaction between CYP2C19 and CYP2D6 effects. CONCLUSION: Despite several limitations including the lack of serum drug levels, this study showed that variations in CYP2C19 were associated with tolerance and remission in a large sample of White non-Hispanic patients treated with citalopram.
Authors: Hua Tang; Tom Quertermous; Beatriz Rodriguez; Sharon L R Kardia; Xiaofeng Zhu; Andrew Brown; James S Pankow; Michael A Province; Steven C Hunt; Eric Boerwinkle; Nicholas J Schork; Neil J Risch Journal: Am J Hum Genet Date: 2004-12-29 Impact factor: 11.025
Authors: J J Swen; I Wilting; A L de Goede; L Grandia; H Mulder; D J Touw; A de Boer; J M H Conemans; T C G Egberts; O H Klungel; R Koopmans; J van der Weide; B Wilffert; H-J Guchelaar; V H M Deneer Journal: Clin Pharmacol Ther Date: 2008-02-06 Impact factor: 6.875
Authors: Michael E Thase; Barbara R Haight; Nathalie Richard; Carol B Rockett; Melinda Mitton; Jack G Modell; Susan VanMeter; April E Harriett; Younghua Wang Journal: J Clin Psychiatry Date: 2005-08 Impact factor: 4.384
Authors: L L von Moltke; D J Greenblatt; J M Grassi; B W Granda; K Venkatakrishnan; S X Duan; S M Fogelman; J S Harmatz; R I Shader Journal: Biol Psychiatry Date: 1999-09-15 Impact factor: 13.382
Authors: D A Mrazek; A J Rush; J M Biernacka; D J O'Kane; J M Cunningham; E D Wieben; D J Schaid; M S Drews; V L Courson; K A Snyder; J L Black; R M Weinshilboum Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-04-05 Impact factor: 3.568
Authors: Staffan Ohlsson Rosenborg; Jessica Mwinyi; Maria Andersson; R Michael Baldwin; Rasmus Steen Pedersen; Sarah C Sim; Leif Bertilsson; Magnus Ingelman-Sundberg; Erik Eliasson Journal: Eur J Clin Pharmacol Date: 2008-07-25 Impact factor: 2.953
Authors: Whitney E Kramer; Denise L Walker; Dennis J O'Kane; David A Mrazek; Pamela K Fisher; Brian A Dukek; Jamie K Bruflat; John L Black Journal: Pharmacogenet Genomics Date: 2009-10 Impact factor: 2.089
Authors: Eric J Peters; Susan L Slager; Jeffrey B Kraft; Greg D Jenkins; Megan S Reinalda; Patrick J McGrath; Steven P Hamilton Journal: PLoS One Date: 2008-04-02 Impact factor: 3.240
Authors: Jeffrey R Bishop; Fedra Najjar; Leah H Rubin; Stephen J Guter; Thomas Owley; Matthew W Mosconi; Suma Jacob; Edwin H Cook Journal: Pharmacogenet Genomics Date: 2015-11 Impact factor: 2.089
Authors: V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta Journal: Clin Pharmacol Ther Date: 2012-02-08 Impact factor: 6.875
Authors: C A Altar; J M Carhart; J D Allen; D K Hall-Flavin; B M Dechairo; J G Winner Journal: Pharmacogenomics J Date: 2015-02-17 Impact factor: 3.550
Authors: C Anthony Altar; Joseph Carhart; Josiah D Allen; Daniel Hall-Flavin; Joel Winner; Bryan Dechairo Journal: Mol Neuropsychiatry Date: 2015-07-31